# CJC-1295: Extending a Hormone Signal > CJC-1295 Research Overview — Research Peptide Fundamentals — Core Peptides Lab — Research Peptide Fundamentals research peptides: a cited CJC-1295 overview of DAC and no-DAC forms, GHRH signaling, small human pharmacology studies, and safety limits. **REFERENCE FILE 02 / GH AXIS** A modified GHRH analog that raises growth hormone and IGF-1 in small human studies while leaving clinical benefit and long-term safety unsettled. ## The short version CJC-1295 is a laboratory-made version of growth-hormone-releasing hormone, often shortened to GHRH. Natural GHRH tells the pituitary gland to release growth hormone. CJC-1295 was modified so that the signal lasts longer. The long-acting form contains a Drug Affinity Complex, or DAC, that binds the peptide to albumin, a common blood protein. Small studies in healthy adults show that the DAC form can raise growth hormone and insulin-like growth factor 1, or IGF-1, for days while normal pulses of growth-hormone release continue [11][12]. Those are pharmacology findings: they show that the compound reaches and affects its intended signaling system. They do not show improved sleep, recovery, muscle, body composition, or healthy aging. CJC-1295 is not an approved medicine. Published human research is early, small, and short term. The DAC and no-DAC forms behave very differently, yet informal discussions often mix their names. Any careful account must identify the form and must separate measured hormone changes from claims of clinical benefit. ## What it is CJC-1295 is built on the first twenty-nine amino acids of human growth-hormone-releasing factor. Four substitutions help the peptide resist common breakdown routes and stabilize its active shape. In the DAC version, a chemical linker reacts with a free sulfur group on circulating albumin. The resulting albumin attachment extends exposure into a multi-day range. The label “CJC-1295” is used inconsistently. Proper CJC-1295 with DAC is long acting. “Modified GRF 1-29,” sometimes marketed as CJC-1295 no-DAC, retains the four stabilizing substitutions but lacks the albumin-binding part and is short acting. Findings from one form cannot simply be transferred to the other. A modern review places the compound within the larger class of GHRH analogs and explains why longer-acting designs were developed [8]. Analytical researchers have also identified CJC-1295 in an unknown preparation from an anti-doping context, illustrating a gap between a named product and verified chemical identity [9]. ## How it works CJC-1295 binds the GHRH receptor on somatotroph cells in the front part of the pituitary gland. That receptor activates a Gs, cyclic-AMP, and protein-kinase-A signaling pathway. The immediate result is increased synthesis and release of growth hormone. Growth hormone then acts on the liver and other tissues, including stimulation of IGF-1 production. The mechanism remains upstream of growth hormone: CJC-1295 is not growth hormone itself. This distinction matters because the compound stimulates the body's release pattern rather than replacing the hormone directly. In a human study, basal hormone levels rose while the frequency and size of natural growth-hormone pulses remained essentially preserved [12]. The DAC form's albumin binding accounts for its prolonged action. The same persistence that makes it useful for studying continuous GHRH stimulation also extends exposure to downstream GH and IGF-1 signals. That is a pharmacologic feature with both research value and unresolved safety implications. ## What the research shows *Hormone response.* In healthy adults, single studied administrations produced dose-dependent increases in mean growth hormone for at least six days and IGF-1 for nine to eleven days. Following repeated study administrations, IGF-1 remained above baseline for as long as twenty-eight days. The estimated half-life was between 5.8 and 8.1 days [11]. These figures apply to the DAC compound and cited study conditions. *Preserved pulsatility.* In healthy men, one study found an approximately 7.5-fold rise in basal growth hormone, with mean growth hormone about 46% higher and IGF-1 about 45% higher one week later. The frequency and magnitude of hormone pulses did not materially change [12]. *Proteomic observations.* A study of eleven healthy young men found changes in several serum proteins after CJC-1295 exposure. Signals involving immunoglobulin and an albumin fragment correlated with IGF-1, suggesting possible biomarkers of GH-axis activation [10]. *Context rather than outcomes.* A current GHRH review describes the wider receptor pharmacology and therapeutic landscape [8]. The composed corpus contains no large, long-term outcome trial establishing that CJC-1295 improves health, performance, sleep, recovery, or body composition. Its human evidence demonstrates target engagement, not an approved clinical benefit. ## Reported effects, cautions & safety The reports summarized here are **anecdotal, not clinical evidence**. Research-use communities very commonly mention deeper sleep and frequently mention workout recovery, gradual fat loss, a leaner appearance, or muscle retention. Occasional themes include energy, focus, and firmer-feeling skin. The most common unwanted report is water retention or puffiness, followed by hand tingling, injection-site reactions, flushing, fatigue, headache, increased appetite when combined with other compounds, and higher blood-sugar readings. These accounts cannot separate CJC-1295 from training, sleep changes, companion compounds, placebo effects, or uncertain product identity. The established studies are too small and brief to define broad safety. Sustained GH and IGF-1 elevation is directly demonstrated [11][12], so concerns about fluid retention, glucose regulation, and prolonged growth signaling have a plausible mechanistic basis even when a specific long-term harm has not been shown. CJC-1295 has no approved human indication. Form confusion adds a practical evidence problem. Multi-day DAC exposure and short-acting Modified GRF 1-29 are not interchangeable. The analytical identification of CJC-1295 in an unknown preparation also shows why a label alone cannot verify contents [9]. CJC-1295 is prohibited in competitive sport, and the corpus notes unresolved development history and regulator concerns about immune responses. Those issues warrant caution without overstating causality. ## Where it fits in Research Peptide Fundamentals CJC-1295 represents **measurable human target engagement without mature clinical outcomes**. Unlike the mostly animal BPC-157 record, its core hormone effect has been measured directly in people. Unlike an approved therapy, however, it lacks large outcome trials, an established indication, and long-term safety data. The file also teaches a naming lesson: chemical form can change duration and risk interpretation. That principle carries to [GHK-Cu](/ghk-cu), where copper binding and topical delivery matter, and to [KPV](/kpv), where nanoparticle and hydrogel systems are part of the experiment. See the [comparison](/compare) for the four evidence profiles together. ![Abstract CJC-1295 research illustration in aubergine and violet](/images/cjc-1295.webp) --- Core Peptides Lab is an independent reading desk for four distinct peptide research records, with study context in view and no clinical counsel offered.